ArticleAdvances in therapy2026
Real-World Use of Abrocitinib for Moderate-to-Severe Atopic Dermatitis in the United States Based on Electronic Health Records and Administrative Claims.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAbrocitinib is approved for moderate-to-severe atopic dermatitis (AD) treatment. Real-world abrocitinib usage data are limited. The aim of this study was to characterize patients initiating abrocitinib in clinical settings in the United States.
methodsRetrospective, observational study of patients aged ≥ 12 years with AD using linked claims (index date: abrocitinib initiation) and electronic health records in the OMNY Health real-world data platform (January 1, 2017-October 31, 2025). Baseline demographics, characteristics, comorbidities, medication history, and healthcare resource utilization were evaluated. Abrocitinib dose changes ≤ 12 months post-index, early persistence (prescription refill within 60 days of index), and AD severity changes from baseline were assessed.
resultsOverall, 401 patients initiated abrocitinib (8.5% adolescent; 91.5% adult). Mean time since diagnosis was 4.2 years. Most patients (72.1%) received abrocitinib as their first advanced systemic therapy and the most common starting dose was 100 mg (81.8%). The most frequent pre-index AD therapy overall was topical treatment (72.6%). Within 12 months post-index, 90.8% of patients remained on the starting dose and 60.8% demonstrated early persistence.
conclusionMost patients with moderate-to-severe AD prescribed abrocitinib receive 100 mg as the starting dose, refill their prescription within 60 days of index, and maintained their starting dose. Limitations include incomplete patient data and lack of generalizability to other settings.
Indexed as
Identifiers
42667571What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.